Welcome to Markets Desk, here's what's moving the needle this afternoon.
Disney's live-action Moana is topping the domestic box office, but the numbers behind that headline tell a rougher story. The film cost a reported two hundred fifty million dollars to produce and pulled in just forty-three million domestically in its opening weekend, with fifty-two million more from international markets. For a franchise this size, that's a underwhelming debut that will raise hard questions inside Burbank about the economics of live-action remakes going forward.
Shifting to biotech, where insider activity is drawing attention on two names. At Kymera Therapeutics, the chief executive exercised and immediately sold fifty thousand shares at one hundred nineteen dollars per share, realizing roughly six million dollars in proceeds following a one hundred seventy percent run in the stock. Separately, an Immunome insider offloaded one hundred thousand shares for two point four million dollars just one day before a significant FDA milestone, a move that markets will be watching closely for what it may or may not signal about expectations.
And in labor news, the Justice Department has convened a federal grand jury to investigate UAW President Shawn Fain, probing allegations that he pressured a senior union official to secure benefits for his fiancée and her sister. A subpoena has been issued to the union's court-appointed monitor, adding legal pressure to an already scrutinized organization.
That's the tape. Markets Desk, signing off the floor.
